EB-DNK102
/ Beijing Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 05, 2026
DUAL-NK-PDAC: Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
(clinicaltrials.gov)
- P1/2 | N=42 | Recruiting | Sponsor: Beijing Biotech
Biomarker • New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CLDN18 • MSLN
1 to 1
Of
1
Go to page
1